Compare Enveric Biosciences Inc (ENVB) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nucor Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Nucor Corporation trades at $248.72 (market cap $55.84B). The key difference: Nucor Corporation is far larger — about 8211.8× Enveric Biosciences Inc's market cap, and Nucor Corporation pays a 0.91% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Nucor Corporation for 78 Days on average.
| ENVB | NUE | |
|---|---|---|
Market Cap | $6.80M | $55.84B |
Volume | 64,867 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $274.74 |
52-Week Low | $1.27 | $131.78 |
Typical Hold Time | 14 Days | 78 Days |
Enterprise Value | -$1.49M | $60.25B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Nucor (NUE) trades at $246.44, down 1.84% on the day, with a neutral technical signal and mixed earnings history including a Q2 2026 beat. Revenue and net income have shown volatility, with 2025 revenue at $32.49B and net income at $1.74B, while analyst consensus is a 'Buy' with a $266.88 price target. Recent news highlights steel sector dynamics and Nucor's Q3 2026 earnings guidance.
The outlook for NUE is cautiously optimistic, supported by analyst bullishness and projected earnings growth, but risks include competitive pressures from new steel capacity and cyclical demand fluctuations. Investment opportunity lies in its solid fundamentals and dividend history, though investors should weigh margin pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
